Influence of drug class and dose size on antibiotic-induced endotoxin/IL-6 release and impact on efficacy of anti-endotoxin antibody

Journal of Endotoxin Research

Volumn 3, Issue 3, 1996, Pages 219-227

  Healy, Daniel P ^a   Verst Brasch, Cynthia L ^b   Clendening, Chris E ^b   Neely, Alice N ^c   Holder, Ian Alan ^c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; ENDOTOXIN; ENDOTOXIN ANTIBODY; GENTAMICIN; IMIPENEM; INTERLEUKIN 6; MEROPENEM; MONOCLONAL ANTIBODY; PIPERACILLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BURN; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG EFFICACY; INTRAPERITONEAL DRUG ADMINISTRATION; KLEBSIELLA PNEUMONIAE; MOUSE; NONHUMAN; SEPSIS; SURVIVAL;

ANIMALIA; KLEBSIELLA PNEUMONIAE;

EID: 0029763123     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1177/096805199600300307     Document Type: Conference Paper

References (39)

1. Morrison D.C., Ryan J.L. Endotoxins and disease mechanisms. Annu Rev Med 1987; 38: 417-432.
2. Rietschel E.T., Schade U., Jensen M. et al. Bacterial endotoxin: chemical structure, biological activity and role in septicaemia. Scand J Infect Dis 1982; 31 (Suppl): 8-21.
3. Glauser M.P., Heumann D., Baumgartner J.D., Cohen J. Pathogenesis and potential strategies for prevention and treatment of septic shock: an update. Clin Infect Dis 1994; 18 (Suppl 2): S205-S216.
4. Goto H., Nakamura S. Liberation of endotoxin from E. coli by addition of antibiotics. Jpn J Exp Med 1980; 50: 35-43.
5. Jackson J.J., Kropp H. β-lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 1992; 165: 1033-1041.
6. McConnell J.S., Cohen J. Release of endotoxin from Escherichia coli by quinolones. J Antimicrob Chemother 1986; 18: 765-773.
7. Van den Berg C., De Neeling A.J., Schot C.S., Hustinx W.N.M., Wemer J., De Wildt D.J. Delayed antibiotic-induced lysis of Escherichia coli in vitro is correlated with enhancement of LPS release. Scand J Infect Dis 1992; 24: 619-627.
8. Walterspiel J.W., Kaplan S.L., Mason E.O. Protective effect of subinhibitory polymyxin B alone and in combination with ampicillin for overwhelming Haemophilus influenzae type B infection in the infant rat: evidence for in vivo and in vitro release of free endotoxin after ampicillin treatment. Pediatr Res 1986; 20: 237-241.
9. Shenep J.L., Barton R.P., Mogan K.A. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. J Infect Dis 1985; 151: 1012-1018.
10. Crosby H.A., Bion J.F., Penn C.W., Elliott T.S.J. Antibiotic-induced release of endotoxin from bacteria in vitro. J Med Microbiol 1994; 40: 23-30.
11. Evans M.E., Pollack M. Effect of antibiotic class and concentration on the release of lipopolysaccharide from Escherichia coli. J Infect Dis 1993; 167: 1336-1343.
12. Eng R.H.K., Smith S.M., Fan-Havard P., Ogbara T. Effect of antibiotics on endotoxin release from gram-negative bacteria. Diagn Microbiol Infect Dis 1993; 16: 185-189.
13. Buijs J., Dofferhoff A.S.M. Antibiotic-induced endotoxin release is type, dose and schedule dependent (abstract A97). In: ProGram-and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington, DC: American Society for Microbiology, 1994; 147.
14. Hurley J.C. Antibiotic-induced release of endotoxin: a reappraisal. Clin Infect Dis 1992; 15: 840-854.
15. Prins J.M., van Deventer S.J.H., Kuijper E.J., Speelman P. Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother 1994; 38: 1211-1218.
16. Prins J.M., van Agtmael M.A., Kuijper E.J., van Deventer S.J.H., Speelman P. Antibiotic-induced endotoxin release in patients with gram-negative urosepsis: a double-blind study comparing imipenem and ceftazidime. J Infect Dis 1995; 172: 886-891.
17. Shenep J.L., Flynn P.M., Barrett F.F., Stidham G.L., Westenkirchner D.F. Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis. J Infect Dis 1988; 157: 565-568.
18. Dofferhoff A.S.M., Nijland J.H., de Vries-Hospers H.G., Mulder P.O.M., Weits J., Bom V.J.J. Effects of different types and combinations of antimicrobial agents on endotoxin release from Gram-negative bacteria: an in vitro and in vivo study. Scand J Infect Dis 1991; 23: 745-754.
19. Dofferhoff A.S.M., Bom V.J.J., de Vries-Hospers H.G. et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992; 20: 185-192.
20. Shenep J.L., Mogan K.A. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis 1984; 150: 380-388.
21. Dofferhoff A.S.M., Potthoff H., Bom V.J.J. et al. The release of endotoxin, TNF and IL-6 during the antibiotic treatment of experimental gram-negative sepsis. J Endotoxin Res 1995; 2: 37-44.
22. Cross A.S., Opal S.M., Sadoff J.C., Gemski P. Choice of bacteria in animal models of sepsis. Infect Immun 1993; 61: 2741-2747.
23. Holder I.A., Jogan M. Enhanced survival in burn mice treated with antiserum prepared against normal and burned skin. J Trauma 1971; 11: 1041-1046.
24. Stieritz D.D., Holder I.A. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. J Infect Dis 1975; 131: 688-691.
25. Neely A.N., Holder I.A. A murine model with aspects of clinical relevance for the study of antibiotic-induced endotoxin release in septic hosts. J Endotoxin Res 1996; 3: 229-235.
26. Neely A.N., Miller R., Holder I.A. Proteolytic activity and fatal Gram-negative sepsis in burns: effect of exogenous proteinase inhibition. Infect Immun 1994; 62: 2158-2162.
27. Hurley J.C. Endotoxemia: methods of detection and clinical correlates. Clin Microbiol Rev 1995; 8: 268-292.
28. Kusser W.C., Ishiguro E.E. Effects of aminoglycosides and spectinomycin on the synthesis and release of lipopolysaccharide by Escherichia coli. Antimicrob Agents Chemother 1988; 32: 1247-1250.
29. Leggett J.E., Ebert S., Fantin B., Craig W.A. Comparative dose effect relations of several dosing intervals for beta-lactam, aminoglycoside, and quinolone antibiotics against Gram-negative bacilli in a murine thigh-infection and pneumonitis models. Scand J Infect Dis 1991; 74 (Suppl.1): 179-184.
30. Siegel S.A., Evans M.E., Pollack M. et al. Antibiotics enhance binding of human lipid-A reactive monoclonal antibody HA-1A to smooth gram-negative bacteria. Infect Immun 1993; 61: 512-519.
31. Overbeek B.P., Veringa E.M. Role of antibodies and antibiotics in aerobic gram-negative septicemia: possible role of synergism between antimicrobial treatment and immunotherapy. Rev Infect Dis 1991; 13: 751-760.
32. Ziegler E.J., Fisher Jr C.J., Sprung C.L. et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324: 429-436.
33. Greenman R.L., Schein R.M.H., Martin M.A. et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266: 1097-1102.
34. McCloskey R.V., Straube R.C., Sanders C. et al. Treatment of septic shock rath human monoclonal antibody HA-1A. Ann Intern Med 1994; 121: 1-5.
35. Bone R.C., Balk R.A., Fein A.M. et al. A second large controlled clinical trial of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23: 994-1006.
36. Mock C.N., Jurkovich G.J., Dries D.J., Maier R.V. Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch Surg 1995; 130: 1234-1241.
37. Collins H.H., Cross A.S., Dobek A., Opal S.M., McClain J.B., Sadoff J.C. Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis 1989; 159: 1073-1082.
38. Romulo R.L.C., Palardy J.E., Opal S.M. Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis. J Infect Dis 1993; 167: 126-130.
39. Lundblad R., Giercksky K.E. Synergistic effect of E5, imipenem, and volume support during fulminant intraabdominal sepsis in mis. J Infect Dis 1995; 172: 152-160.